In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients

Autor: M. W. F. van Spengler, Ron A. A. Mathôt, Tim Preijers, Frank W.G. Leebeek, Marjon H. Cnossen, K. Fijnvandraat, Karina Meijer, Krista Fischer

Publikováno v: European Journal of Clinical Pharmacology, 78(2), 237-249. Springer-Verlag
European Journal of Clinical Pharmacology, 78(2), 237-249. Springer Verlag
European journal of clinical pharmacology, 78(2). Springer Verlag
European journal of clinical pharmacology, 78(2), 237-249. Springer Verlag
European Journal of Clinical Pharmacology

Purpose Hemophilia B is a bleeding disorder, caused by a factor IX (FIX) deficiency. Recently, FIX concentrates with extended half-life (EHL) have become available. Prophylactic dosing of EHL-FIX concentrates can be optimized by assessment of individ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f10d2a8fc4fb713c022f2191d679c460
http://www.scopus.com/inward/record.url?scp=85116989191&partnerID=8YFLogxK